As the results of intensive studies, the present inventors identified transcription factors that control the expression of semaphorin 3A gene. By inhibiting or promoting these transcription factors, the expression of semaphorin 3A can be controlled (suppressed or enhanced). Further, by screening compounds with the use of an activity of inhibiting or promoting such a transcription factor as an index, a compound capable of controlling the expression of semaphorin 3A can be obtained. The compound capable of controlling the expression of semaphorin 3A is useful in treating itch in skin diseases, allergic rhinitis, osteoporosis and nerve damage, in particular, for treating itch.
